vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
First Foundation Inc. is the larger business by last-quarter revenue ($48.4M vs $27.5M, roughly 1.8× Sanara MedTech Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -97.9%, a 92.0% gap on every dollar of revenue. On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 4.6%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $-35.2M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs -2.7%).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
FFWM vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $27.5M |
| Net Profit | $-8.0M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | -97.5% | 23.5% |
| Net Margin | -97.9% | -5.9% |
| Revenue YoY | 421.7% | 4.6% |
| Net Profit YoY | 43.0% | 5.3% |
| EPS (diluted) | $-0.09 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $27.5M | ||
| Q3 25 | $63.6M | $26.3M | ||
| Q2 25 | $51.4M | $25.8M | ||
| Q1 25 | $71.4M | $23.4M | ||
| Q4 24 | $9.3M | $26.3M | ||
| Q3 24 | $9.2M | $21.7M | ||
| Q2 24 | $57.5M | $20.2M | ||
| Q1 24 | $51.1M | $18.5M |
| Q4 25 | $-8.0M | $-1.6M | ||
| Q3 25 | $-146.3M | $-30.4M | ||
| Q2 25 | $-7.7M | $-2.0M | ||
| Q1 25 | $6.9M | $-3.5M | ||
| Q4 24 | $-14.1M | $-1.7M | ||
| Q3 24 | $-82.2M | $-2.9M | ||
| Q2 24 | $3.1M | $-3.5M | ||
| Q1 24 | $793.0K | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | -97.5% | 23.5% | ||
| Q3 25 | -92.7% | 11.2% | ||
| Q2 25 | -21.1% | -0.1% | ||
| Q1 25 | 8.8% | -8.9% | ||
| Q4 24 | -247.7% | 18.6% | ||
| Q3 24 | -1276.7% | 3.6% | ||
| Q2 24 | 4.6% | -14.3% | ||
| Q1 24 | -0.2% | -8.3% |
| Q4 25 | -97.9% | -5.9% | ||
| Q3 25 | -230.1% | -115.5% | ||
| Q2 25 | -15.0% | -7.8% | ||
| Q1 25 | 9.7% | -15.1% | ||
| Q4 24 | -152.2% | -6.5% | ||
| Q3 24 | -896.9% | -13.2% | ||
| Q2 24 | 5.4% | -17.4% | ||
| Q1 24 | 1.6% | -9.5% |
| Q4 25 | $-0.09 | $-0.32 | ||
| Q3 25 | $-1.78 | $-3.40 | ||
| Q2 25 | $-0.09 | $-0.23 | ||
| Q1 25 | $0.08 | $-0.41 | ||
| Q4 24 | $-0.24 | $-0.18 | ||
| Q3 24 | $-1.23 | $-0.34 | ||
| Q2 24 | $0.05 | $-0.41 | ||
| Q1 24 | $0.01 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $912.6M | $5.9M |
| Total Assets | $11.9B | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $16.6M | ||
| Q3 25 | $1.7B | $14.9M | ||
| Q2 25 | $1.1B | $17.0M | ||
| Q1 25 | $1.0B | $20.7M | ||
| Q4 24 | $1.0B | $15.9M | ||
| Q3 24 | $1.1B | $16.3M | ||
| Q2 24 | $1.4B | $6.2M | ||
| Q1 24 | $1.6B | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $912.6M | $5.9M | ||
| Q3 25 | $917.9M | $6.1M | ||
| Q2 25 | $1.1B | $35.4M | ||
| Q1 25 | $1.1B | $36.7M | ||
| Q4 24 | $1.1B | $39.4M | ||
| Q3 24 | $1.1B | $39.8M | ||
| Q2 24 | $933.2M | $41.7M | ||
| Q1 24 | $928.7M | $43.3M |
| Q4 25 | $11.9B | $72.9M | ||
| Q3 25 | $11.9B | $71.1M | ||
| Q2 25 | $11.6B | $98.8M | ||
| Q1 25 | $12.6B | $96.4M | ||
| Q4 24 | $12.6B | $88.1M | ||
| Q3 24 | $13.4B | $88.5M | ||
| Q2 24 | $13.7B | $73.4M | ||
| Q1 24 | $13.6B | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $3.9M |
| Free Cash FlowOCF − Capex | $-35.2M | $3.9M |
| FCF MarginFCF / Revenue | -72.8% | 14.0% |
| Capex IntensityCapex / Revenue | 6.9% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $3.9M | ||
| Q3 25 | $9.2M | $2.2M | ||
| Q2 25 | $-16.3M | $2.7M | ||
| Q1 25 | $-552.0K | $-2.0M | ||
| Q4 24 | $-8.7M | $932.0K | ||
| Q3 24 | $14.2M | $2.1M | ||
| Q2 24 | $-9.1M | $-1.4M | ||
| Q1 24 | $7.2M | $-1.6M |
| Q4 25 | $-35.2M | $3.9M | ||
| Q3 25 | $8.6M | $1.1M | ||
| Q2 25 | $-16.7M | $902.7K | ||
| Q1 25 | $-2.5M | $-3.7M | ||
| Q4 24 | $-11.4M | $859.9K | ||
| Q3 24 | $13.4M | $2.0M | ||
| Q2 24 | $-9.4M | $-1.5M | ||
| Q1 24 | $5.9M | $-1.7M |
| Q4 25 | -72.8% | 14.0% | ||
| Q3 25 | 13.5% | 4.2% | ||
| Q2 25 | -32.4% | 3.5% | ||
| Q1 25 | -3.5% | -15.9% | ||
| Q4 24 | -123.5% | 3.3% | ||
| Q3 24 | 146.2% | 9.4% | ||
| Q2 24 | -16.3% | -7.3% | ||
| Q1 24 | 11.6% | -9.0% |
| Q4 25 | 6.9% | 0.3% | ||
| Q3 25 | 1.0% | 4.0% | ||
| Q2 25 | 0.8% | 6.8% | ||
| Q1 25 | 2.8% | 7.4% | ||
| Q4 24 | 29.4% | 0.3% | ||
| Q3 24 | 9.0% | 0.0% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 2.5% | 0.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FFWM
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
